Chemotherapy followed by half-body radiation therapy for canine lymphoma

Journal of Veterinary Internal Medicine

Volumn 18, Issue 5, 2004, Pages 703-709

  Williams, Laurel E ^a   Johnson, Jeffrey L ^b   Hauck, Marlene L ^a   Ruslander, David M ^a,c   Price, G Sylvester ^a,d   Thrall, Donald E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c Veterinary Specialty Hospital of the Carolinas   (United States)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Cancer; Dog; Multimodality therapy

Indexed keywords

ASPARAGINASE; CHLORAMBUCIL; COBALT 60; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; COBALT THERAPY; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; LYMPHOMA; MAINTENANCE THERAPY; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHENOTYPE; PHOTON; PREDICTION; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; SKULL IRRADIATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOG DISEASES; DOGS; FEMALE; HEMIBODY IRRADIATION; LYMPHOMA; MALE; RADIOTHERAPY DOSAGE; REMISSION INDUCTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 6444226777     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<703:CFBHRT>2.0.CO;2     Document Type: Article

References (36)

1. Stone MS, Goldstein MA, Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. J Am Anim Hosp Assoc 1991;27:315-321.
2. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
3. Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug combination chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
4. Zemann BI, Moore AS, Rand, WM, et al. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Intern Med 1998;12:465-470.
5. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
6. Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
7. Cowall DE, MacVittie TJ, Parker GA, Weinberg SR. Effects of low-dose total-body irradiation on canine bone marrow function and canine lymphoma. Exp Hematol 1981;9:581-587.
8. Fajardo L-G LF. Morphology of radiation effects on normal tissues. In: Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology, 3rd ed. Philadelphia, PA: Lippincott-Raven; 1998: 143-154.
9. Laing EJ, Fitzpatrick PJ, Binnington AG, et al. Half-body radiotherapy in the treatment of canine lymphoma. J Vet Intern Med 1989; 3:102-108.
10. Owen, L. TNM classification of tumors in domestic animals. Geneva: WHO; 1980:46-47.
11. National Cancer Institute, National Institutes of Health. Common Toxicity Criteria, version 2.0. Bethesda, MD: National Institutes of Health; 1999:6, 22-31.
12. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley; 1973.
13. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220.
14. Simon R, Lee YJ. Nonparametric confidence limits for survival probabilities and median survival time. Cancer Treat Rep 1982;66: 37-42.
15. Hall EJ. Acute effects of total-body irradiation. In: Radiobiology for the Radiologist. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:124-135.
16. Pitson G, Fyles A. Editorial: Perils and pitfalls of clinical trials - Experience from human oncology. J Vet Intern Med 2000;14: 392-394.
17. MacEwen EG, Brown NO, Patnaik AK, et al. Cyclic combination chemotherapy of canine lymphosarcoma. J Am Vet Med Assoc 1981;178:1178-1181.
18. Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine, and prednisone: I. Treatment of dogs. J Am Anim Hosp Assoc 1983;19:159-165.
19. Carter RF, Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation: Doxorubicin alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987;23:587-596.
20. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs: A morphologic, immunologic, and clinical study. Cancer 1990; 66:480-490.
21. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
22. Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002; 119:1405-1410.
23. Edinger M, Cao YA, Verneris MR, et al. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101:640-648.
24. Maggio E, van den Berg A, Diepstra A, et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13(Suppl 1):52-56.
25. Catena C, Conti D, Villani P, Righi E. Micronuclei and 3AB index in human and canine lymphocytes after in vitro X-irradiation. Mutat Res 1994;312:1-8.
26. Edgren J, Weber TH. Radiation sensitivity of lymphocytes from human blood and from the thoracic duct. Acta Radiol Ther Phys Biol 1976;15:177-182.
27. Yarilin AA, Polushkina Et, Anokhin YN. Radioresistant T lymphocytes in mice: Distribution in organs, Thy-1 antigen content and helper activity. Immunology 1980;40:565-569.
28. Arase N, Arase H, Good RA, Onoe K. Contribution of host radioresistant T cells to the clonal elimination of minor lymphocyte stimulatory-1a reactive T cells in mouse bone marrow chimeras. Cell Immunol 1994;156:13-23.
29. Louagie H, Van Eijkeren M, Philippe J, et al. Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int J Radiat Biol 1999;75:767-771.
30. Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998;77:1103-1107.
31. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998;91:2272-2282.
32. Intragumtornchai T, Rotnakkarin P, Sutcharitchan P, Wannagrairoj P. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:52-55.
33. Ruslander DA, Gebhard DH, Tompkins MB, et al. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 1997;11:169-172.
34. Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991;67:1389-1395.
35. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-2221.
36. Coiffier B. The impact and management of anaemia in hematological malignancies. Med Oncol 2000;17(Suppl 1):S2-S10.